Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.[4][5] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.[6]
^"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
^"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^Cite error: The named reference Finn2009 was invoked but never defined (see the help page).
^Cite error: The named reference pmid24369047 was invoked but never defined (see the help page).
^"Updated Data from Phase 3 Trial of Ibrance (palbociclib) Plus Letrozole in HR+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival" (Press release). Pfizer. Archived from the original on 22 June 2021. Retrieved 16 December 2017.
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast...
additionally evaluate the efficacy and safety of inavolisib in combination with palbociclib and fulvestrant in patients that have PIK3CA-mutated, locally advanced...
as has been shown in a study with rifampicin. Like the related drugs palbociclib and ribociclib, abemaciclib inhibits the enzymes cyclin-dependent kinase...
HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given...
overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal...
revenues), a pneumococcal conjugate vaccine ($6 billion in 2023 revenues), palbociclib ($4 billion in 2023 revenues), and tafamidis ($3 billion in 2023 revenues)...
monotherapy and in combination with other drugs such as the CDK inhibitor palbociclib (Ibrance). Aromatase inhibitor Estrogen deprivation therapy Lee, Clara...
therapeutic target for anti-tumor effectiveness. Three Cdk4/6 inhibitors – palbociclib, ribociclib, and abemaciclib – currently received FDA approval for clinical...
toremifene and fulvestrant, often used in combination with CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib). When one endocrine therapy fails, most...
teams has contributed to the development of two FDA-approved treatments; palbociclib (Breast Cancer Dream Team), and abraxane plus gemcitabine (Pancreatic...
Clinical trial number NCT03065062 for "Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib...
and FDA clinical approval of three small molecule CDK4/6 inhibitors (Palbociclib (IBRANCE, Pfizer Inc. 2015), Ribociclib (KISQUALI, Novartis. 2017), &...
Global Information
